Brain-Computer Interface Moving Toward Reality: This Year, Over 100 Institutions Have Investigated 5 Concept Stocks

People’s Financial News, March 24 — According to the National Healthcare Security Administration, on March 13, the world’s first invasive brain-computer interface medical device was officially approved for market launch. On March 15, the National Healthcare Security Administration proactively coordinated and provided services to assign medical insurance codes to this product, successfully bridging the critical gap from approval and market entry to clinical application. This marks the transition of the brain-computer interface industry from a “planning blueprint” to an “accelerated implementation phase.” According to data from Securities Times and Data Treasure, since the beginning of the year, 12 brain-computer interface concept stocks have been surveyed by institutions. Among them, five stocks—Xiangyu Medical, Aipeng Medical, Entropy Technology, Botuo Biotech, and Sanqi Interactive Entertainment—have been investigated by over 110 institutions each. As of the close on March 23, the total market value of brain-computer interface concept stocks in A-shares is 475.497 billion yuan. Since the start of the year, these stocks have generally declined, with an average retracement of 30.96% compared to the high point earlier this year, based on the March 23 closing prices. Hige Communication, Prite, Xiangyu Medical, and Botuo Biotech experienced the largest declines.